SPARC’s Starhaler Device shortlisted as finalist at 2012 MDEA

11 Apr 2012 Evaluate

Sun Pharma Advanced Research Company’s (SPARC) Combitide Starhaler for asthma and COPD is shortlisted as a finalist at the 2012 Medical Design Excellence Awards (MDEA) to be held in Philadelphia this May. Combitide Starhaler has been introduced in the Indian market last year by Sun Pharmaceutical Industries.

Combitide Starhaler is a novel, high performance multi dose dry powder inhaler. This next generation DPI improves on current marketed devices. The inhaler has a uniform delivery profile that ensures that the full intended metered dose of the drug is administered to the deep lung, regardless of the strength of the patient’s intake of breath. This step change in inhaler technology offers a reliable and easy to use device, particularly for patients with impaired lung function.

MDEA is the premier awards program for the medical technology community, and the only awards program that exclusively recognizes contributions and advances in the design of medical products. 

Sun Pharma Adv. Res Share Price

190.40 -5.70 (-2.91%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 847.55
Sagility India 28.27
AGS Transact Tech 79.58
Just Dial 1050.60
Krystal Integrated 638.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.